Effects of External Ear Stimulation on Pain Perception and Mood
NCT02821741
Recruiting
Background: The vagus nerve runs from the brain to many organs. Stimulating it can affect the experience of pain. The nerve can be stimulated on the surface of the left ear. Researchers want to study how this stimulation affects the perception of pain. They also want to study how mood affects the experience of pain. Objective: To study the effects of mood and vagus nerve stimulation on the experience of pain. Eligibility: Healthy people ages 18 and older who are fluent in English Design:... Read More
Gender:
ALL
Ages:
Between 18 years and 50 years
Trial Updated:
06/12/2025
Locations: National Institutes of Health Clinical Center, Bethesda, Maryland
Conditions: Pain in Healthy Participants
Register for Updates
APOL1 Long-term Kidney Transplantation Outcomes Network (APOLLO)
NCT03615235
Recruiting
The APOLLO study is being done in an attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from ki... Read More
Gender:
ALL
Ages:
All
Trial Updated:
06/12/2025
Locations: University of Alabama at Birmingham, Birmingham, Alabama +17 locations
Conditions: Kidney Diseases, Kidney Failure, Kidney Disease, Chronic
Register for Updates
RESOLVE: Abemaciclib + Letrozole +/- Metformin, Zotatifin, or Gedatolisib in Endometrial or Low-Grade Serous Ovarian Cancer
NCT03675893
Recruiting
This research study is studying a combination of targeted therapies as a possible treatment for estrogen-receptor positive (ER+) endometrial cancer and low-grade serous ovarian cancer. The drugs involved in this study are: * Abemaciclib (also known as Verzenio™) * Letrozole (also known as Femara®) * Metformin (also known as Glucophage®) * Zotatifin (also known as eFT226) * Gedatolisib (also known as PF-05212384)
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Massachusetts General Hospital Cancer Center, Boston, Massachusetts +2 locations
Conditions: Endometrial Cancer, Ovarian Cancer
Register for Updates
Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)
NCT04150497
Recruiting
This is a first-in-human, open-label, dose escalation and expansion study of UCART22 administered intravenously to patients with relapsed or refractory B-cell acute Lymphoblastic Leukemia (B-ALL). The purpose of this study is to evaluate the safety and clinical activity of UCART22 and determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D)
Gender:
ALL
Ages:
Between 15 years and 50 years
Trial Updated:
06/12/2025
Locations: University of California, Los Angeles (UCLA) - Medical Center, Los Angeles, California +17 locations
Conditions: B-cell Acute Lymphoblastic Leukemia
Register for Updates
PET/CT Changes During Chemoimmunotherapy and Radiation Therapy in Patients With Stage IV Non-small Cell Lung Cancer
NCT04151940
Recruiting
This study investigates the changes in positron emission tomography (PET)/computed tomography (CT) imaging scans during chemoimmunotherapy and radiation therapy treatment in patients with stage IV non-small cell lung cancer. Analyzing changes in PET/CT imaging scans may help doctors assess and predict patterns of cancer response to chemoimmunotherapy and radiation therapy.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington
Conditions: Metastatic Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8
Register for Updates
KEYMAKER-U01 Umbrella Master Study: Studies of Investigational Agents With Either Pembrolizumab (MK-3475) Alone or With Pembrolizumab PLUS Chemotherapy in Participants With Non-small Cell Lung Cancer (NSCLC) (MK-3475-U01/KEYMAKER-U01)
NCT04165798
Recruiting
This study is referred to as the "umbrella master protocol" for pembrolizumab (MK-3475) in the treatment of non-small cell lung cancer (NSCLC). This pembrolizumab NSCLC umbrella master protocol uses a platform design and consists of this master screening study and seven substudies. Each substudy will enroll a different population of NSCLC participants. The goal of this umbrella master protocol is to screen potential participants with NSCLC for enrollment into 1 of 7 substudies. Participants mus... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Banner MD Anderson Cancer Center ( Site 0001), Gilbert, Arizona +39 locations
Conditions: Carcinoma, Non-Small-Cell Lung
Register for Updates
Evaluation of the Clinical and Psychological Impact of Vitamin D Replacement in Adolescent Females at Risk for Polycystic Ovarian Syndrome (PCOS)
NCT04355572
Recruiting
This study is a double blind, placebo controlled, randomized trial of study subjects with PCOS and low vitamin D to 2 groups- placebo and vitamin D replacement. Participants and investigators will be blinded to treatment modality until the end of the trial period
Gender:
FEMALE
Ages:
Between 13 years and 21 years
Trial Updated:
06/12/2025
Locations: Yale New Haven Children's Hospital, New Haven, Connecticut
Conditions: Polycystic Ovarian Syndrome in Adolescent Females, Vitamin D Deficiency
Register for Updates
Cabozantinib in High Grade Neuroendocrine Neoplasms
NCT04412629
Recruiting
High grade neuroendocrine neoplasm patients are treated with platinum doublets such as carboplatin and etoposide mimicking the current guidelines for small cell lung cancer (SCLC). Unfortunately, recurrences are common and most patients with metastatic disease succumb to it within a year. There is no extensive literature or consensus on second- or third-line options (which include FOLFOX, FOLFIRI, capecitabine and temozolomide, taxanes or immunotherapy) and there is urgent need for better regime... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/12/2025
Locations: Washington University School of Medicine, Saint Louis, Missouri
Conditions: High Grade Neuroendocrine Neoplasms
Register for Updates
Approach-Avoidance, Computational Framework for Predicting Behavioral Therapy Outcome (AAC-BeT)
NCT04426461
Recruiting
Depression and anxiety disorders rank in the top ten causes of years lived with disability. Less than 50% of patients experiencing long-lasting improvements to current gold-standard treatments. Two gold-standard behavioral interventions include behavioral activation, focused on enhancing approach behavior towards meaningful activities, and exposure-based therapy, focused on decreasing avoidance and challenging negative expectations. While these interventions have divergent treatment targets, the... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/12/2025
Locations: Laureate Institute for Brain Research, Tulsa, Oklahoma
Conditions: Anxiety, Depression
Register for Updates
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462
Recruiting
The purpose of this study is to evaluate the long-term safety and tolerability, of open label iptacopan in primary IgA nephropathy participants who have completed either the CLNP023X2203 or CLNP023A2301 clinical trials. The open-label design of the current study is appropriate to provide study participants the opportunity to receive treatment with iptacopan until marketing authorizations are received and the drug product becomes commercially available while enabling collection of long-term safet... Read More
Gender:
ALL
Ages:
Between 18 years and 100 years
Trial Updated:
06/12/2025
Locations: AZ Kidney Dise and Hypertension Ctr, Glendale, Arizona +145 locations
Conditions: Primary IgA Nephropathy
Register for Updates
Congenital Uterine Anomalies: Identifying Cancer Associations and Genetic and Environmental Factors to Improve Clinical Care
NCT04661072
Recruiting
The purpose of this research study is to learn more about the health outcomes associated with congenital uterine anomalies (CUAs), and the possible environmental and genetic causes of the condition. The researchers plan to investigate whether any cancer associations (with breast, renal, ovarian, vaginal and uterine cancers) exist in females with CUAs. The investigator will also investigate any environmental and genetic factors that may be responsible for causing CUAs.
Gender:
FEMALE
Ages:
13 years and above
Trial Updated:
06/12/2025
Locations: Yale University, New Haven, Connecticut
Conditions: Congenital Uterine Anomaly
Register for Updates
University of Pittsburgh Brain Health Initiative
NCT04708613
Recruiting
This project will define the prevalence of brain health (i.e., normal cognitive, neuromotor, behavioral function) in living professional football retirees and group-matched controls through a comprehensive assessment of clinical, neuroimaging, and biomarker measures.
Gender:
MALE
Ages:
Between 29 years and 59 years
Trial Updated:
06/12/2025
Locations: University of Pittsburgh Department of Neurosurgery, Pittsburgh, Pennsylvania
Conditions: Traumatic Brain Injury
Register for Updates